Daxor Corporation (DXR)vsNovartis AG ADR (NVS)
DXR
Daxor Corporation
$10.60
-4.39%
HEALTHCARE · Cap: $61.88M
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 211981912% more annual revenue ($56.58B vs $26,690). DXR leads profitability with a 34359.0% profit margin vs 23.9%. DXR trades at a lower P/E of 6.5x. NVS earns a higher WallStSmart Score of 49/100 (D+).
DXR
Hold45
out of 100
Grade: D+
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXR.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 34359 of every $100 in revenue as profit
Earnings expanding 329.3% YoY
Conservative balance sheet, low leverage
Every $100 of equity generates 23 in profit
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 82.6%
Negative free cash flow — burning cash
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 34359.0% and operating margin at -9661.0%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : DXR
The primary concerns for DXR are Market Cap, Piotroski F-Score, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (49/100 vs 45/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?